Literature DB >> 19047088

Perilobar nephrogenic rests are nonobligate molecular genetic precursor lesions of insulin-like growth factor-II-associated Wilms tumors.

Raisa Vuononvirta1, Neil J Sebire, Anthony R Dallosso, Jorge S Reis-Filho, Richard D Williams, Alan Mackay, Kerry Fenwick, Anita Grigoriadis, Alan Ashworth, Kathy Pritchard-Jones, Keith W Brown, Gordan M Vujanic, Chris Jones.   

Abstract

PURPOSE: Perilobar nephrogenic rests (PLNRs) are abnormally persistent foci of embryonal immature blastema that have been associated with dysregulation at the 11p15 locus by genetic/epigenetic means and are thought to be precursor lesions of Wilms tumor. The precise genomic events are, however, largely unknown. EXPERIMENTAL
DESIGN: We used array comparative genomic hybridization to analyze a series of 50 PLNRs and 25 corresponding Wilms tumors characterized for 11p15 genetic/epigenetic alterations and insulin-like growth factor-II expression.
RESULTS: The genomic profiles of PLNRs could be subdivided into three categories: those with no copy number changes (22 of 50, 44%); those with single, whole chromosome alterations (8 of 50, 16%); and those with multiple gains/losses (20 of 50, 40%). The most frequent aberrations included 1p- (7 of 50, 14%) +18 (6 of 50, 12%), +13 (5 of 50, 10%), and +12 (3 of 50, 6%). For the majority (19 of 25, 76%) of cases, the rest harbored a subset of the copy number changes in the associated Wilms tumor. We identified a temporal order of genomic changes, which occur during the insulin-like growth factor-II/PLNR pathway of Wilms tumorigenesis, with large-scale chromosomal alterations such as 1p-, +12, +13, and +18 regarded as "early" events. In some of the cases (24%), the PLNRs harbored large-scale copy number changes not observed in the concurrent Wilms tumor, including +10p, +14q, and +18.
CONCLUSIONS: These data suggest that although the evidence for PLNRs as precursors is compelling, not all lesions must necessarily undergo malignant transformation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19047088      PMCID: PMC2659869          DOI: 10.1158/1078-0432.CCR-08-1620

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  35 in total

1.  Functional significance of type 1 insulin-like growth factor-mediated nuclear translocation of the insulin receptor substrate-1 and beta-catenin.

Authors:  Jia Chen; An Wu; Hongzhi Sun; Robert Drakas; Cecilia Garofalo; Sandra Cascio; Eva Surmacz; Renato Baserga
Journal:  J Biol Chem       Date:  2005-06-20       Impact factor: 5.157

2.  Genomic profiling maps loss of heterozygosity and defines the timing and stage dependence of epigenetic and genetic events in Wilms' tumors.

Authors:  Eric Yuan; Chi-Ming Li; Darrell J Yamashiro; Jessica Kandel; Harshwardhan Thaker; Vundavalli V Murty; Benjamin Tycko
Journal:  Mol Cancer Res       Date:  2005-09       Impact factor: 5.852

3.  Genome-wide loss of heterozygosity analysis of WT1-wild-type and WT1-mutant Wilms tumors.

Authors:  E Cristy Ruteshouser; Brett W Hendrickson; Stefano Colella; Ralf Krahe; Lancelot Pinto; Vicki Huff
Journal:  Genes Chromosomes Cancer       Date:  2005-06       Impact factor: 5.006

4.  Age distributions, birth weights, nephrogenic rests, and heterogeneity in the pathogenesis of Wilms tumor.

Authors:  Norman E Breslow; J Bruce Beckwith; Elizabeth J Perlman; Anthony E Reeve
Journal:  Pediatr Blood Cancer       Date:  2006-09       Impact factor: 3.167

5.  Global variation in copy number in the human genome.

Authors:  Richard Redon; Shumpei Ishikawa; Karen R Fitch; Lars Feuk; George H Perry; T Daniel Andrews; Heike Fiegler; Michael H Shapero; Andrew R Carson; Wenwei Chen; Eun Kyung Cho; Stephanie Dallaire; Jennifer L Freeman; Juan R González; Mònica Gratacòs; Jing Huang; Dimitrios Kalaitzopoulos; Daisuke Komura; Jeffrey R MacDonald; Christian R Marshall; Rui Mei; Lyndal Montgomery; Kunihiro Nishimura; Kohji Okamura; Fan Shen; Martin J Somerville; Joelle Tchinda; Armand Valsesia; Cara Woodwark; Fengtang Yang; Junjun Zhang; Tatiana Zerjal; Jane Zhang; Lluis Armengol; Donald F Conrad; Xavier Estivill; Chris Tyler-Smith; Nigel P Carter; Hiroyuki Aburatani; Charles Lee; Keith W Jones; Stephen W Scherer; Matthew E Hurles
Journal:  Nature       Date:  2006-11-23       Impact factor: 49.962

6.  Association of 11q loss, trisomy 12, and possible 16q loss with loss of imprinting of insulin-like growth factor-II in Wilms tumor.

Authors:  Naoki Watanabe; Hisaya Nakadate; Masayuki Haruta; Waka Sugawara; Fumiaki Sasaki; Yukiko Tsunematsu; Atsushi Kikuta; Masahiro Fukuzawa; Hajime Okita; Jun-ichi Hata; Hidenobu Soejima; Yasuhiko Kaneko
Journal:  Genes Chromosomes Cancer       Date:  2006-06       Impact factor: 5.006

7.  Wilms tumor suppressor WTX negatively regulates WNT/beta-catenin signaling.

Authors:  Michael B Major; Nathan D Camp; Jason D Berndt; Xianhua Yi; Seth J Goldenberg; Charlotte Hubbert; Travis L Biechele; Anne-Claude Gingras; Ning Zheng; Michael J Maccoss; Stephane Angers; Randall T Moon
Journal:  Science       Date:  2007-05-18       Impact factor: 47.728

8.  Array CGH profiling of favourable histology Wilms tumours reveals novel gains and losses associated with relapse.

Authors:  R Natrajan; R D Williams; S N Hing; A Mackay; J S Reis-Filho; K Fenwick; M Iravani; H Valgeirsson; A Grigoriadis; C F Langford; O Dovey; S G Gregory; B L Weber; A Ashworth; P E Grundy; K Pritchard-Jones; C Jones
Journal:  J Pathol       Date:  2006-09       Impact factor: 7.996

9.  Blastemal expression of type I insulin-like growth factor receptor in Wilms' tumors is driven by increased copy number and correlates with relapse.

Authors:  Rachael Natrajan; Jorge S Reis-Filho; Suzanne E Little; Boo Messahel; Marie-Anne Brundler; Jeffrey S Dome; Paul E Grundy; Gordan M Vujanic; Kathy Pritchard-Jones; Chris Jones
Journal:  Cancer Res       Date:  2006-12-01       Impact factor: 12.701

10.  Array CGH using whole genome amplification of fresh-frozen and formalin-fixed, paraffin-embedded tumor DNA.

Authors:  Suzanne E Little; Raisa Vuononvirta; Jorge S Reis-Filho; Rachael Natrajan; Marjan Iravani; Kerry Fenwick; Alan Mackay; Alan Ashworth; Kathy Pritchard-Jones; Chris Jones
Journal:  Genomics       Date:  2005-11-02       Impact factor: 5.736

View more
  12 in total

1.  Molecular characterization of Wilms' tumor from a resource-constrained region of sub-Saharan Africa.

Authors:  Andrew J Murphy; Jason R Axt; Christian de Caestecker; Janene Pierce; Hernan Correa; Erin H Seeley; Richard M Caprioli; Mark W Newton; Mark P de Caestecker; Harold N Lovvorn
Journal:  Int J Cancer       Date:  2012-04-04       Impact factor: 7.396

2.  Deletions of 16q in Wilms tumors localize to blastemal-anaplastic cells and are associated with reduced expression of the IRXB renal tubulogenesis gene cluster.

Authors:  Linda Holmquist Mengelbier; Jenny Karlsson; David Lindgren; Ingrid Øra; Margareth Isaksson; Ildiko Frigyesi; Attila Frigyesi; Johannes Bras; Bengt Sandstedt; David Gisselsson
Journal:  Am J Pathol       Date:  2010-09-16       Impact factor: 4.307

Review 3.  Pediatric genitourinary tumors.

Authors:  Sharon M Castellino; Anibal R Martinez-Borges; Thomas W McLean
Journal:  Curr Opin Oncol       Date:  2009-05       Impact factor: 3.645

4.  Loss of imprinting of IGF2 and the epigenetic progenitor model of cancer.

Authors:  Mark B Leick; Christopher J Shoff; Erwin C Wang; Jaclyn L Congress; G Ian Gallicano
Journal:  Am J Stem Cells       Date:  2011-08-19

5.  Expression of hepatocyte growth factor and its receptor met in Wilms' tumors and nephrogenic rests reflects their roles in kidney development.

Authors:  Raisa Vuononvirta; Neil J Sebire; Boo Messahel; Nina Perusinghe; Jorge S Reis-Filho; Kathy Pritchard-Jones; Gordan M Vujanic; Chris Jones
Journal:  Clin Cancer Res       Date:  2009-03-24       Impact factor: 12.531

6.  A distinct spectrum of copy number aberrations in pediatric high-grade gliomas.

Authors:  Dorine A Bax; Alan Mackay; Suzanne E Little; Diana Carvalho; Marta Viana-Pereira; Narinder Tamber; Anita E Grigoriadis; Alan Ashworth; Rui M Reis; David W Ellison; Safa Al-Sarraj; Darren Hargrave; Chris Jones
Journal:  Clin Cancer Res       Date:  2010-06-22       Impact factor: 12.531

7.  Constitutional de novo deletion of the FBXW7 gene in a patient with focal segmental glomerulosclerosis and multiple primitive tumors.

Authors:  Gaia Roversi; Chiara Picinelli; Ilaria Bestetti; Milena Crippa; Daniela Perotti; Sara Ciceri; Fabiana Saccheri; Paola Collini; Pietro L Poliani; Serena Catania; Bernard Peissel; Fabio Pagni; Silvia Russo; Paolo Peterlongo; Siranoush Manoukian; Palma Finelli
Journal:  Sci Rep       Date:  2015-10-20       Impact factor: 4.379

8.  The IGF signalling pathway in Wilms tumours--a report from the ENCCA Renal Tumours Biology-driven drug development workshop.

Authors:  Mariana Maschietto; Jocelyn Charlton; Daniela Perotti; Paolo Radice; James I Geller; Kathy Pritchard-Jones; Mark Weeks
Journal:  Oncotarget       Date:  2014-09-30

9.  The first investigation of Wilms' tumour atomic structure-nitrogen and carbon isotopic composition as a novel biomarker for the most individual approach in cancer disease.

Authors:  Katarzyna Taran; Tomasz Frączek; Anita Sikora-Szubert; Anna Sitkiewicz; Wojciech Młynarski; Józef Kobos; Piotr Paneth
Journal:  Oncotarget       Date:  2016-11-22

10.  Comparative methylome analysis identifies new tumour subtypes and biomarkers for transformation of nephrogenic rests into Wilms tumour.

Authors:  Jocelyn Charlton; Richard D Williams; Neil J Sebire; Sergey Popov; Gordan Vujanic; Tasnim Chagtai; Marisa Alcaide-German; Tiffany Morris; Lee M Butcher; Paul Guilhamon; Stephan Beck; Kathy Pritchard-Jones
Journal:  Genome Med       Date:  2015-02-02       Impact factor: 11.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.